An autologous, mRNA-engineered TCR-T cell therapy in which a patient’s T cells are transiently redirected to express HBV antigen–specific T-cell receptors that recognize HBV-derived peptides presented by HLA-A*02:01 or HLA-A*24:02 on tumor cells, inducing TCR/MHC class I–dependent activation and cytotoxic killing of HBV-related hepatocellular carcinoma; administered IV weekly at 5–10×10^6 cells/kg.